Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CODX
stocks logo

CODX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
126.00K
-15.62%
-0.120
-66.67%
163.50K
+225.18%
-0.125
-47.92%
166.50K
+2.2%
-0.100
-56.52%
Estimates Revision
The market is revising No Change the revenue expectations for Co-Diagnostics, Inc. (CODX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 24.76%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+3.42%
In Past 3 Month
Stock Price
Go Up
up Image
+24.76%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Co-Diagnostics Inc (CODX.O) is -0.88, compared to its 5-year average forward P/E of 6.18. For a more detailed relative valuation and DCF analysis to assess Co-Diagnostics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
6.18
Current PE
-0.88
Overvalued PE
23.87
Undervalued PE
-11.52

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
5.58
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
23.73
Undervalued EV/EBITDA
-12.57

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
12.67
Current PS
0.00
Overvalued PS
25.03
Undervalued PS
0.30
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

CODX News & Events

Events Timeline

(ET)
2025-11-05
09:04:49
Co-Diagnostics appoints Maxim Group as financial advisor for CoSara Diagnostics
select
2025-11-04 (ET)
2025-11-04
08:45:02
Significant Borrowing Rate Hikes Among Liquid Assets
select
2025-11-03 (ET)
2025-11-03
09:04:24
Co-Diagnostics establishes a new division focused on AI
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
12-03NASDAQ.COM
CoDiagnostics (CODX) Receives Upgrade to Buy: Key Information You Need to Know

  • Zacks Rank Upgrade: Co-Diagnostics, Inc. (CODX) has been upgraded to a Zacks Rank #2 (Buy) due to an upward trend in earnings estimates, indicating a positive outlook for the company's stock price.

  • Earnings Estimate Revisions: The Zacks rating system, which correlates earnings estimate revisions with stock price movements, shows that Co-Diagnostics has seen an 8.9% increase in its consensus earnings estimate over the past three months.

  • Investment Strategy: The Zacks Rank system classifies stocks based on earnings estimates, with only the top 20% receiving a "Buy" or "Strong Buy" rating, suggesting that Co-Diagnostics is well-positioned for potential market-beating returns.

  • Future Projections: Analysts predict that Co-Diagnostics will earn -$0.72 per share for the fiscal year ending December 2025, with expectations of continued growth in the company's underlying business driving investor interest.

[object Object]
Preview
4.0
11-27NASDAQ.COM
Maxim Group Begins Coverage of Co-Diagnostics (CODX) with a Buy Rating

  • Maxim Group Coverage: On November 26, 2025, Maxim Group initiated coverage of Co-Diagnostics (NasdaqCM:CODX) with a Buy recommendation, projecting a 527.69% upside based on an average one-year price target of $2.04/share.

  • Projected Revenue and EPS: Co-Diagnostics is expected to see a 201.25% increase in annual revenue, reaching $2 million, with a projected non-GAAP EPS of 0.38.

  • Fund Sentiment: There are currently 42 funds reporting positions in Co-Diagnostics, with a slight decrease in ownership but an increase in total shares owned by institutions by 6.63% over the last three months.

  • Shareholder Activity: Notable shareholders include Vanguard Total Stock Market Index Fund and Renaissance Technologies, the latter increasing its holdings by 35.33% in the last quarter.

[object Object]
Preview
3.5
11-20PRnewswire
Co-Diagnostics Delivers Address about Tuberculosis Test Adoption and Implementation at The Union World Conference on Lung Health

  • Company Announcement: Co-Diagnostics, Inc. announced that Joseph Featherstone, the Executive Vice President of Business Development, spoke at the 2025 World Conference on Lung Health in Copenhagen, discussing the adoption of a tuberculosis molecular diagnostic test.

  • New Testing Technology: The company is set to begin clinical performance testing of its new Co-Dx™ PCR Mycobacterium Tuberculosis Test Kit, which aims to improve tuberculosis testing in India and South Africa through decentralized PCR technology.

  • Strategic Plans: Co-Diagnostics is exploring a strategic transaction, potentially a merger with a SPAC, for its Indian joint venture, CoSara Diagnostics, to enhance the availability of high-quality molecular diagnostic products.

  • Regulatory Status: The Co-Dx PCR platform and associated tests are currently under review by regulatory bodies and are not yet available for sale.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Co-Diagnostics Inc (CODX) stock price today?

The current price of CODX is 0.3865 USD — it has increased 8.41 % in the last trading day.

arrow icon

What is Co-Diagnostics Inc (CODX)'s business?

Co-Diagnostics, Inc. is a molecular diagnostics company, which develops, manufactures and markets diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. It is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the user’s mobile device.

arrow icon

What is the price predicton of CODX Stock?

Wall Street analysts forecast CODX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CODX is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Co-Diagnostics Inc (CODX)'s revenue for the last quarter?

Co-Diagnostics Inc revenue for the last quarter amounts to 145.38K USD, decreased -77.32 % YoY.

arrow icon

What is Co-Diagnostics Inc (CODX)'s earnings per share (EPS) for the last quarter?

Co-Diagnostics Inc. EPS for the last quarter amounts to -0.16 USD, decreased -50.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Co-Diagnostics Inc (CODX)'s fundamentals?

The market is revising No Change the revenue expectations for Co-Diagnostics, Inc. (CODX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 24.76%.
arrow icon

How many employees does Co-Diagnostics Inc (CODX). have?

Co-Diagnostics Inc (CODX) has 132 emplpoyees as of December 05 2025.

arrow icon

What is Co-Diagnostics Inc (CODX) market cap?

Today CODX has the market capitalization of 23.53M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free